FDA releases fresh details on internal debate over controversial Alzheimer’s drug
The new information, included in interviews with agency officials and 83 pages of internal documents, might not quiet a furor over the drug Aduhelm that has drawn in Alzheimer’s doctors and patients, members of Congress, Medicare officials, and the agency itself.
View original article
Contributor: Laurie McGinley